Ferguson Lynnette R, Chen Helen, Collins Andrew R, Connell Marisa, Damia Giovanna, Dasgupta Santanu, Malhotra Meenakshi, Meeker Alan K, Amedei Amedeo, Amin Amr, Ashraf S Salman, Aquilano Katia, Azmi Asfar S, Bhakta Dipita, Bilsland Alan, Boosani Chandra S, Chen Sophie, Ciriolo Maria Rosa, Fujii Hiromasa, Guha Gunjan, Halicka Dorota, Helferich William G, Keith W Nicol, Mohammed Sulma I, Niccolai Elena, Yang Xujuan, Honoki Kanya, Parslow Virginia R, Prakash Satya, Rezazadeh Sarallah, Shackelford Rodney E, Sidransky David, Tran Phuoc T, Yang Eddy S, Maxwell Christopher A
Discipline of Nutrition, University of Auckland, Auckland, New Zealand.
Department of Pediatrics, University of British Columbia, Michael Cuccione Childhood Cancer Research Program, Child and Family Research Institute, Vancouver, Canada.
Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S5-S24. doi: 10.1016/j.semcancer.2015.03.005. Epub 2015 Apr 11.
Genomic instability can initiate cancer, augment progression, and influence the overall prognosis of the affected patient. Genomic instability arises from many different pathways, such as telomere damage, centrosome amplification, epigenetic modifications, and DNA damage from endogenous and exogenous sources, and can be perpetuating, or limiting, through the induction of mutations or aneuploidy, both enabling and catastrophic. Many cancer treatments induce DNA damage to impair cell division on a global scale but it is accepted that personalized treatments, those that are tailored to the particular patient and type of cancer, must also be developed. In this review, we detail the mechanisms from which genomic instability arises and can lead to cancer, as well as treatments and measures that prevent genomic instability or take advantage of the cellular defects caused by genomic instability. In particular, we identify and discuss five priority targets against genomic instability: (1) prevention of DNA damage; (2) enhancement of DNA repair; (3) targeting deficient DNA repair; (4) impairing centrosome clustering; and, (5) inhibition of telomerase activity. Moreover, we highlight vitamin D and B, selenium, carotenoids, PARP inhibitors, resveratrol, and isothiocyanates as priority approaches against genomic instability. The prioritized target sites and approaches were cross validated to identify potential synergistic effects on a number of important areas of cancer biology.
基因组不稳定可引发癌症、促进肿瘤进展并影响受影响患者的总体预后。基因组不稳定源于许多不同的途径,如端粒损伤、中心体扩增、表观遗传修饰以及内源性和外源性来源导致的DNA损伤,并且可通过诱导突变或非整倍体而持续存在或受到限制,这两者既具有促成作用又具有灾难性。许多癌症治疗会诱导DNA损伤以在全球范围内损害细胞分裂,但人们也认为必须开发个性化治疗方法,即针对特定患者和癌症类型量身定制的治疗方法。在本综述中,我们详细阐述了基因组不稳定产生并导致癌症的机制,以及预防基因组不稳定或利用基因组不稳定引起的细胞缺陷的治疗方法和措施。特别是,我们确定并讨论了针对基因组不稳定的五个优先靶点:(1)预防DNA损伤;(2)增强DNA修复;(3)靶向缺陷的DNA修复;(4)破坏中心体聚集;以及(5)抑制端粒酶活性。此外,我们强调维生素D和B、硒、类胡萝卜素、聚(ADP-核糖)聚合酶(PARP)抑制剂、白藜芦醇和异硫氰酸盐是对抗基因组不稳定的优先方法。对这些优先靶点和方法进行交叉验证,以确定其在癌症生物学多个重要领域的潜在协同效应。